Cipla Medpro, a 100% subsidiary of Cipla Limited, has a strong presence across therapies in the Republic of South Africa. Cipla also won government tenders in antiretrovirals (ARV), respiratory and newer areas such as mental health, cardiovascular and women’s health categories.
Cipla’s manufacturing facility at Durban provides a competitive edge and is the first Pharmaceutical Inspection Convention (PIC) compliant facility in the country. The brand inspires trust and has become a household name amongst consumers, pharmacies, prescribers and key opinion leaders.
Cipla has a clear commitment to provide access to Africa and other LDCs (Least Developed Countries). Cipla Quality Chemical Industries Limited ( CiplaQCIL ) is a state of the art manufacturing plant in Uganda that manufactures WHO prequalified anti-retrovirals antimalarials and antivirals for the treatment of hepatitis B. The plant is the largest in East Africa and supplies the Ugandan market and exports to East Africa, Cameroon and various markets in southern Africa. CiplaQCIL is currently expanding its portfolio to manufacture medicines for tropical diseases such as sleeping sickness, worm infestations and hepatitis C.
For more information visit us at www.cipla.co.za